Product logins

Find logins to all Clarivate products below.


Contrast Agents and Radiopharmaceuticals | Market Insights | US | 2021

The COVID-19 pandemic will have a significant impact on the US diagnostic imaging market in the short term. Once the market stabilizes, however, the contrast agents and radiopharmaceuticals market in US will see modest growth through 2029 driven by a growing aging population, increases in health risk factors like poor lifestyle, and adoption of new technology due to favorable regulatory changes. However, overall market expansion will be hindered by a saturated installed base of large imaging systems as well as consolidation of hospitals.

Growth in the US market for contrast agents and radiopharmaceuticals will be driven by the expanded use of imaging agents in CEUS and PET procedures. However, the market will be somewhat limited by the continued concern over gadolinium and radiation exposure in certain modalities, while the shift to value-based care will hinder the use of some procedures while supporting the use of those that provide the most accuracy and clarity of visualization.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in the US across a 10-year period.

Related Medtech Insights Reports

Report
Contrast Agents and Radiopharmaceuticals – Market Insights – United States
The US contrast agents and radiopharmaceutical market will see moderate growth over the forecast period. Market growth will be driven by rising PET and MRI procedure volumes, and the expanding use…
Report
Contrast Agents and Radiopharmaceuticals | Market Insights | US | 2024
The US contrast agents and radiopharmaceutical market was severely impacted by the COVID-19 pandemic in 2020, but has already shown significant recovery in 2021 and 2022; however, it continues to…
Report
Contrast Agents and Radiopharmaceuticals – Market Insights – Europe
The COVID-19 pandemic negatively impacted the European contrast agents and radiopharmaceutical market in 2020. Following the recovery, growth in the European market will be supported by the…
Report
Contrast Agents and Radiopharmaceuticals | Market Insights | US | 2022
The global COVID-19 pandemic has negatively impacted the US contrast agents and radiopharmaceutical market to some extent. During the initial onset of the pandemic and at periods of high local…
Report
Contrast Agents and Radiopharmaceuticals | Market Insights | Europe | 2022
Although demand for contrast-enhanced CT for the diagnosis and monitoring of COVID-19 cases has slightly mitigated the impact of the global pandemic on the European contrast agent and…